MedTrace Logo

huC242-DM4 Treating Patients With Metastatic Gastric or Gastroesophageal Junction Carcinomas

NCT00620607 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2015-08-26

No results posted yet for this study

Summary

To assess the response rate of huC242-DM4 given as an intravenous infusion to patients with metastatic or locally advanced gastric or gastroesophageal junction cancer.

Conditions

  • Stomach Neoplasms
  • Metastatic or Locally Advanced Gastric Cancer
  • Metastatic or Local Advanced GE Junction Cancer

Interventions

DRUG

huC242-DM4

dose of 126 mg/m2 or 168 mg/m2 given as IV once every 3 weeks

Sponsors & Collaborators

  • ImmunoGen, Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2010-05-31
Completion
2010-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00620607 on ClinicalTrials.gov